Buprenorphine and Netupitant: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Netupitant
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Your body normally uses a liver enzyme called CYP3A4 to break down buprenorphine, the opioid medicine. Netupitant slows that enzyme down. That means buprenorphine can build up in your blood and act stronger and last longer than usual.
Why does that matter? Too much buprenorphine can cause heavy drowsiness and, in serious cases, slowed breathing. This is worth taking seriously, but it is very manageable. Please don't stop or change either medicine on your own. Let your pharmacist or doctor know you take both, so they can tailor your dose and keep a closer eye on you while you're on them together.
Mechanism: Netupitant inhibits CYP3A4-mediated metabolism of buprenorphine, increasing buprenorphine plasma exposure. Buprenorphine is not a prodrug, so inhibition increases its effect.
Effect: Elevated buprenorphine concentrations with risk of prolonged opioid effects, including sedation and respiratory depression. Severity major; evidence probable; onset unspecified.
Management:
- If starting netupitant, consider reducing buprenorphine dose until stable, and monitor sedation and respiratory status frequently.
- On discontinuation of the inhibitor, consider increasing buprenorphine and watch for withdrawal.
- For subQ (Sublocade/Brixadi) formulations that limit titration, monitor for over-medication; transition to a more titratable formulation if precise adjustment is needed.
What happens
Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Taking buprenorphine together with a CYP3A4 inhibitor can raise buprenorphine plasma concentrations, potentially resulting in extended opioid effects such as respiratory depression. When a patient on buprenorphine must also receive a CYP3A4 inhibitor, it may be advisable to lower the buprenorphine dose until stable drug effects are reached, while frequently watching for sedation and respiratory depression. Conversely, if a CYP3A4 inhibitor is stopped in a patient maintained on buprenorphine, consider raising the buprenorphine dose until stable effects are attained, and observe for indications of opioid withdrawal2. Should dose adjustment prove impossible once the CYP3A4 inhibitor is gone, switch the patient back to a buprenorphine formulation that allows finer dose titration. For patients moving from transmucosal buprenorphine given alongside CYP3A4 inhibitors, confirm through monitoring that the plasma buprenorphine level delivered by subQ buprenorphine is sufficient. For those already receiving subQ buprenorphine who then need a CYP3A4 inhibitor, watch for indications of over-medication. If manifestations of buprenorphine toxicity or overdose appear and the accompanying medication cannot be lowered or stopped, decrease the buprenorphine dose. When the available doses will not allow the target dose to be reached, halt treatment and manage the patient with a buprenorphine formulation permitting more precise dose adjustments1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both as prescribed unless your care team tells you otherwise. This interaction is manageable with the right adjustments and monitoring.
Here's what a care team typically does:
- May reduce your buprenorphine dose while you are also taking netupitant, then adjust again when netupitant is stopped, so your dose stays individualized to you.
- Monitor you more closely for heavy sedation or slowed breathing, and for withdrawal signs once netupitant ends.
- If you're on a long-acting injectable buprenorphine that is hard to fine-tune, they may switch you to a form that allows more precise dosing.
Call your prescriber or pharmacist if you feel unusually sleepy, confused, or notice slow or shallow breathing.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of concurrently administered CYP3A4 inhibitors on buprenorphine exposure in individuals receiving subQ buprenorphine has not been investigated; nevertheless, these interactions have been demonstrated in studies utilizing transmucosal buprenorphine. Buprenorphine's effects may vary according to the route of administration 1.
Common questions
Can I take Buprenorphine and Netupitant together?
Netupitant can raise buprenorphine levels and increase the risk of excess sedation and slowed breathing. Don't change anything yourself, but tell your pharmacist or doctor so they can adjust your dose and monitor you more closely. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Netupitant interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Netupitant interaction managed?
Keep taking both as prescribed unless your care team tells you otherwise. This interaction is manageable with the right adjustments and monitoring. Here's what a care team typically does: May reduce your buprenorphine dose while you are also taking netupitant, then adjust again when netupitant is stopped, so your dose stays individualized to you. Monitor you more closely for heavy sedation or slow… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Netupitant need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Netupitant
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist